Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

CONTEXT Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies. OBJECTIVE To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of anti-TNF therapy. DATA SOURCES A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews of the manufacturers of the 2 licensed anti-TNF antibodies. STUDY SELECTION We included randomized, placebo-controlled trials of the 2 licensed anti-TNF antibodies (infliximab and adalimumab) used for 12 weeks or more in patients with rheumatoid arthritis. Nine trials met our inclusion criteria, including 3493 patients who received anti-TNF antibody treatment and 1512 patients who received placebo. DATA EXTRACTION Data on study characteristics to assess study quality and intention-to-treat data for serious infections and malignancies were abstracted. Published information from the trials was supplemented by direct contact between principal investigators and industry sponsors. DATA SYNTHESIS We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF-treated patients vs placebo patients. We estimated effects for high and low doses separately. The pooled odds ratio for malignancy was 3.3 (95% confidence interval [CI], 1.2-9.1) and for serious infection was 2.0 (95% CI, 1.3-3.1). Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies. For patients treated with anti-TNF antibodies in the included trials, the number needed to harm was 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months. For serious infections, the number needed to harm was 59 (95% CI, 39-125) within a treatment period of 3 to 12 months. CONCLUSIONS There is evidence of an increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy. The formal meta-analysis with pooled sparse adverse events data from randomized controlled trials serves as a tool to assess harmful drug effects.

[1]  B. Thiers.  Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials , 2007 .

[2]  John T. Wei,et al.  Laparoscopy for renal cell carcinoma: diffusion versus regionalization? , 2006, The Journal of urology.

[3]  F. Wolfe,et al.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology.

[4]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[5]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[6]  W. Britton,et al.  Independent Protective Effects for Tumor Necrosis Factor and Lymphotoxin Alpha in the Host Response to Listeria monocytogenes Infection , 2005, Infection and Immunity.

[7]  C. Turesson,et al.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[8]  D. Barlow,et al.  Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials , 2005, BMJ : British Medical Journal.

[9]  L. Jacobsson,et al.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[10]  I. Nestorov.  Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.

[11]  S. Ehlers,et al.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.

[12]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[13]  J. Hollander,et al.  Trends toward laparoscopic nephrectomy at a community hospital. , 2005, The Journal of urology.

[14]  B. Haraoui.  Differentiating the efficacy of the tumor necrosis factor inhibitors. , 2005, Seminars in arthritis and rheumatism.

[15]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[16]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[17]  L. Klareskog,et al.  Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. , 2005, Arthritis and rheumatism.

[18]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[19]  Silvia Kirchner,et al.  Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. , 2004, Cytokine.

[20]  S. Best,et al.  Minimally invasive therapy for renal cell carcinoma: is there a new community standard? , 2004, Urology.

[21]  F. Wolfe,et al.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. , 2004, Arthritis and rheumatism.

[22]  Alexander J Sutton,et al.  What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.

[23]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[24]  P. van Riel,et al.  Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate , 2004, Scandinavian journal of rheumatology.

[25]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[26]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  R. Dutton,et al.  Effector Cell-Derived Lymphotoxin α and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases , 2004, Cancer Research.

[28]  K. Bendtzen,et al.  TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. , 2004, Clinical and experimental rheumatology.

[29]  N. Sato,et al.  Human tumor necrosis factor increases the resistance against Listeria infection in mice , 2004, Medical Microbiology and Immunology.

[30]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[31]  P. Emery,et al.  Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study , 2003, Annals of the rheumatic diseases.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[34]  Klaus Pfeffer,et al.  Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.

[35]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[36]  H. Paulus,et al.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.

[37]  S. Scheu,et al.  The Lymphotoxin β Receptor Is Critically Involved in Controlling Infections with the Intracellular Pathogens Mycobacterium tuberculosis and Listeria monocytogenes1 , 2003, The Journal of Immunology.

[38]  A. Widmer,et al.  Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003, Rheumatology.

[39]  S. Scheu,et al.  The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. , 2003, Journal of immunology.

[40]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[41]  L. V. D. van de Putte,et al.  A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[42]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[43]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[44]  F. Balkwill.  Tumor necrosis factor or tumor promoting factor? , 2002, Cytokine & growth factor reviews.

[45]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[46]  J. Wolf,et al.  Hand-assisted laparoscopic donor nephrectomy: comparable donor/recipient outcomes, costs, and decreased convalescence as compared to open donor nephrectomy. , 2001, Transplantation proceedings.

[47]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[48]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[49]  G. Macfarlane,et al.  Risk of malignancy among patients with rheumatic conditions , 2000, International journal of cancer.

[50]  I. Olkin,et al.  Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.

[51]  R. Clayman,et al.  Laparoscopic versus open radical nephrectomy: a 9-year experience. , 2000, The Journal of urology.

[52]  P. Lipsky,et al.  Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.

[53]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[54]  P. Beauparlant,et al.  The incidence of cancer associated with the treatment of rheumatoid arthritis. , 1999, Seminars in arthritis and rheumatism.

[55]  L. Smeeth,et al.  Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.

[56]  G A Colditz,et al.  The role of meta-analysis in the regulatory process for foods, drugs, and devices. , 1999, JAMA.

[57]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[58]  J. Escarce,et al.  Externalities in hospitals and physician adoption of a new surgical technology: an exploratory analysis. , 1996, Journal of health economics.

[59]  J. Olsen,et al.  Rheumatoid arthritis and cancer risk. , 1996, European journal of cancer.

[60]  T. Blankenstein,et al.  Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice. , 1995, Blood.

[61]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[62]  P. Mastroeni,et al.  Effect of late administration of anti-TNF alpha antibodies on a Salmonella infection in the mouse model. , 1993, Microbial pathogenesis.

[63]  F. Arnett,et al.  Revised criteria for the classification of rheumatoid arthritis. , 1989, Bulletin on the rheumatic diseases.

[64]  A. Nakane,et al.  Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection , 1988, Infection and immunity.

[65]  N Breslow,et al.  Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.